Yumanity Therapeutics wants to be at the forefront of a neurodegenerative disease revolution, but is taking an unglamorous route to get there.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
2019 was an average year for medtech M&A. 2020, not so much.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Alexion’s move on the anticoagulant reversal specialist is not the most intuitive deal – but is 2020’s second biggest so far.
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.